fda compounding semaglutide warning letters november 2025 Drug compounders sue FDA over declaration ending Wegovy shortage

Compounded Tirzepatide+ Good Life Meds Clinical Focus on GLP 1 Agonists in Type 2 Diabetes Mellitus SELECT Trial: Semaglutide reduces the risk of MACE by 20% in people with overweight or obesity, pre existing CVD, and no diabetes. Average weight loss of 9.4% at 51 months. Does Ozempic Cause Hair Loss? What No One Tells You IDM HOT OFF THE PRESS: Retatrutide Phase 3 data has arrived and the obesity medicine world is paying attention. In Lilly's TRIUMPH 1 trial, participants receiving the highest dose achieved an average